Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.80
CLVS's Cash to Debt is ranked higher than
59% of the 1244 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CLVS: 1.80 )
CLVS' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: 1.8

Interest Coverage No Debt
CLVS's Interest Coverage is ranked higher than
74% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLVS: No Debt )
CLVS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 2.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -976.61
CLVS's Operating margin (%) is ranked higher than
58% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. CLVS: -976.61 )
CLVS' s 10-Year Operating margin (%) Range
Min: 0   Max: 0
Current: -976.61

Net-margin (%) -985.89
CLVS's Net-margin (%) is ranked higher than
58% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.55 vs. CLVS: -985.89 )
CLVS' s 10-Year Net-margin (%) Range
Min: 0   Max: 0
Current: -985.89

ROE (%) -31.30
CLVS's ROE (%) is ranked higher than
75% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CLVS: -31.30 )
CLVS' s 10-Year ROE (%) Range
Min: -144.26   Max: -26.78
Current: -31.3

-144.26
-26.78
ROA (%) -21.88
CLVS's ROA (%) is ranked higher than
76% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: -27.84 vs. CLVS: -21.88 )
CLVS' s 10-Year ROA (%) Range
Min: -65.51   Max: -21.25
Current: -21.88

-65.51
-21.25
ROC (Joel Greenblatt) (%) -9240.49
CLVS's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1220 Companies
in the Global Biotechnology industry.

( Industry Median: -415.02 vs. CLVS: -9240.49 )
CLVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8216.48   Max: -4951.81
Current: -9240.49

-8216.48
-4951.81
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CLVS Guru Trades in Q3 2013

Steven Cohen 1,087,375 sh (+56.74%)
Jim Simons 14,200 sh (-33.64%)
» More
Q4 2013

CLVS Guru Trades in Q4 2013

Steven Cohen 1,166,700 sh (+7.3%)
Jim Simons Sold Out
» More
Q1 2014

CLVS Guru Trades in Q1 2014

Steven Cohen 458,238 sh (-60.72%)
» More
Q3 2014

CLVS Guru Trades in Q3 2014

Jim Simons 22,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.06%$11.65 - $22.5 $ 56.25220%0
John Burbank 2012-09-30 New Buy0.06%$13.55 - $23.15 $ 56.25196%60900
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.92
CLVS's P/B is ranked higher than
77% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 6.37 vs. CLVS: 4.92 )
CLVS' s 10-Year P/B Range
Min: 2.83   Max: 6.01
Current: 4.92

2.83
6.01
P/S 140.63
CLVS's P/S is ranked higher than
67% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. CLVS: 140.63 )
CLVS' s 10-Year P/S Range
Min: 92   Max: 209.58
Current: 140.63

92
209.58
EV-to-EBIT -12.64
CLVS's EV-to-EBIT is ranked lower than
53% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CLVS: -12.64 )
CLVS' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: -8.7
Current: -12.64

-26.2
-8.7
Current Ratio 17.00
CLVS's Current Ratio is ranked higher than
93% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.71 vs. CLVS: 17.00 )
CLVS' s 10-Year Current Ratio Range
Min: 0.86   Max: 31.09
Current: 17

0.86
31.09
Quick Ratio 17.00
CLVS's Quick Ratio is ranked higher than
93% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. CLVS: 17.00 )
CLVS' s 10-Year Quick Ratio Range
Min: 0.86   Max: 31.09
Current: 17

0.86
31.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 26.04
CLVS's Price/Net Cash is ranked higher than
76% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 52.60 vs. CLVS: 26.04 )
CLVS' s 10-Year Price/Net Cash Range
Min: 2.45   Max: 21
Current: 26.04

2.45
21
Price/Net Current Asset Value 24.36
CLVS's Price/Net Current Asset Value is ranked higher than
75% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 31.80 vs. CLVS: 24.36 )
CLVS' s 10-Year Price/Net Current Asset Value Range
Min: 2.45   Max: 19.64
Current: 24.36

2.45
19.64
Price/Tangible Book 19.26
CLVS's Price/Tangible Book is ranked higher than
65% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CLVS: 19.26 )
CLVS' s 10-Year Price/Tangible Book Range
Min: 2.39   Max: 15.53
Current: 19.26

2.39
15.53
Price/Median PS Value 1.15
CLVS's Price/Median PS Value is ranked higher than
83% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. CLVS: 1.15 )
CLVS' s 10-Year Price/Median PS Value Range
Min: 0.85   Max: 1.43
Current: 1.15

0.85
1.43
Earnings Yield (Greenblatt) -7.90
CLVS's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1217 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. CLVS: -7.90 )
CLVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -7.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
comment on CLVS Mar 06 2013 


More From Other Websites
Clovis Oncology 2014 ENA Symposium Update Call scheduled for 8:00 am ET today Nov 21 2014
Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate... Nov 19 2014
Midday movers: Target, JetBlue, Qualcomm & more Nov 19 2014
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly Nov 19 2014
Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical... Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer Nov 18 2014
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline Nov 17 2014
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline Nov 17 2014
CLOVIS ONCOLOGY, INC. Financials Nov 14 2014
Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study Nov 12 2014
CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014
UPDATE: Stifel Reiterates On Clovis Oncology Following 3Q14 LPS Nov 07 2014
Clovis misses 3Q profit forecasts Nov 06 2014
Clovis misses 3Q profit forecasts Nov 06 2014
Clovis Oncology Announces Third Quarter 2014 Operating Results Nov 06 2014
Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today Nov 06 2014
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 06 2014
Clovis Oncology Announces Third Quarter 2014 Operating Results Nov 06 2014
Q3 2014 Clovis Oncology Inc Earnings Release - After Market Close Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK